Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of switching to the study drugs GS-3242 combined with Lenacapavir LEN compared to continuing the standard treatment Biktarvy bictegraviremtricitabinetenofovir alafenamide, BFTAF in adults with HIV-1 infection who are virologically suppressed. This Phase 2 randomized study aims to assess the safety and efficacy of an injectable regimen of GS-3242 plus LEN versus oral BFTAF in different treatment groups over distinct time points, with Part A focusing on Week 35 and Part B on Week 26. Participants are randomly assigned to receive either oral loading doses of GS-3242 and LEN tablets followed by intramuscular IM injections of these drugs for up to 52 weeks, or to continue daily oral BFTAF for the same duration. Different dosing regimens of GS-3242 and LEN are used across groups, with some groups receiving different IM doses. The study includes both randomized and non-randomized groups across the two parts. During the study, participants will be monitored for viral load, specifically HIV-1 RNA levels, using the US FDA Snapshot Algorithm at Weeks 26, 35, and 52, as well as CD4 cell counts. Safety is assessed by recording treatment-emergent adverse events throughout the study period. Drug concentrations are also measured at specific weeks to evaluate pharmacokinetics. The total participant involvement can last up to 52 weeks, with regular assessments to evaluate treatment efficacy and safety.
Actively Recruiting
Researchers are gathering real-world information on the use of lenacapavir LEN, YEZTUGO, YTG as a pre-exposure prophylaxis PrEP to prevent HIV infection in various clinical settings across the United States. The study aims to understand how LEN is started, used, and stopped during routine care and to evaluate how well participants continue using LEN PrEP over time. The main goal is to assess how many participants remain on LEN PrEP at 52 weeks. Participants may choose LEN PrEP through subcutaneous injection or other PrEP options including oral tablets emtricitabinetenofovir disoproxil fumarate or emtricitabinetenofovir alafenamide or intramuscular injections cabotegravir. The study observes participants who select LEN PrEP at enrollment or later and those who choose other PrEP methods or no PrEP. LEN is given via subcutaneous injection, and other drugs are taken orally or by intramuscular injection, depending on the option selected. Participants are followed to track their PrEP use, including how long they continue treatment, interruptions, switching between PrEP types, and coverage days protected by PrEP. The study collects data at enrollment and at weeks 26, 52, 78, and 104. Researchers evaluate persistence on LEN PrEP at week 52 as the primary measure. This observational study does not assign treatments but monitors real-life use of these prevention options over up to two years.
Actively Recruiting
Researchers are evaluating how well a long-acting injectable combination treatment of lenacapavir, teropavimab, and zinlirvimab works compared to continuing daily oral HIV treatment in adults with HIV-1 who already have their virus well controlled. The study focuses on virologically suppressed people with HIV-1 and aims to measure how many participants maintain viral suppression after one year of treatment. Participants in one group will receive an initial dose of oral and injectable lenacapavir along with intravenous infusions of teropavimab and zinlirvimab on Day 1, followed by self-administered oral lenacapavir on Day 2. Every 26 weeks, they will receive additional injections and infusions up to Week 92, with an option to continue in an extension phase. The other group will continue their stable oral antiretroviral therapy as prescribed, also with an option to switch to the injectable combination after Week 92. Throughout the study, participants will be monitored for viral load levels at Weeks 52 and 92 using FDA-approved methods, changes in CD4 T-cell counts, and the presence of antibodies against study drugs. Safety will be assessed by tracking adverse events and treatment discontinuations. Drug levels will also be measured at several timepoints. The study may last until March 2033, including the extension phase for those who continue treatment.
Actively Recruiting
Researchers are evaluating a new long-acting injectable treatment combining lenacapavir LEN, teropavimab TAB, and zinlirvimab ZAB compared to injections of cabotegravir CAB and rilpivirine RPV given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment. The study aims to determine which regimen better maintains viral suppression after one year 52 weeks of treatment. Participants will be randomly assigned to one of two groups. One group receives oral LEN on Day 1, subcutaneous LEN and intravenous infusions of TAB and ZAB on Day 1, then oral LEN on Day 2, followed by subcutaneous LEN and IV infusions of TAB and ZAB every 26 weeks up to Week 92. The other group discontinues their current oral therapy and receives intramuscular injections of CAB and RPV on Day 1, Week 4, and then every 8 weeks up to Week 92. After Week 92, eligible participants may continue LEN TAB ZAB in an extension phase until its completion or discontinuation. During the study, participants will undergo regular monitoring of their HIV-1 RNA levels to assess viral suppression, along with measurements of CD4 T-cell counts. Safety is tracked through adverse event reports and blood tests. The primary outcome is the proportion of participants with HIV-1 RNA at or above 50 copiesmL at Week 52. Secondary outcomes include viral load at Week 92, immune cell changes, drug concentration levels, and antibody development. The total study duration extends up to approximately seven years, including follow-up and extension phases.